OncoMatch/Clinical Trials/NCT05639153
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors
Is NCT05639153 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies DR30303 for malignant neoplasm of digestive system.
Treatment: DR30303 — This study is an open-label Phase 1, First in Human trial of DR30303, a recombinant humanized monoclonal antibody that targets Claudin18.2 (CLDN18.2). It is composed of humanized variable domain of heavy chain of antibody (VHH) fused with engineered immunoglobulin gamma-1(IgG1) Fc. It is being testing against advanced and/or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: CLDN18 positive (positive)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
failed or were intolerant to at least 1 line of systemic therapy
Cannot have received: treatments targeting Claudin18.2
Ever received any treatments targeting Claudin18.2
Cannot have received: radical radiotherapy
Radical radiotherapy was performed within 12 weeks before the first dose of study drug
Cannot have received: systemic anti-tumor therapy
Subjects who have received other systemic anti-tumor therapy within 4 weeks before the first dose of study drug
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify